search
Qilu Pharmaceutical

Qilu Pharmaceutical

Caring through Science & Technology

MORE +
scroll down

聚焦齐鲁

06

/

18

Company News

住济全国人大代表到齐鲁制药参观调研 点赞企业高质量发展

6月18日上午,住济全国人大代表一行,在济南市人大常委会党组副书记、副主任雷天太带领下,到齐鲁制药参观调研,交流代表履职并考察企业发展情况。全国人大代表、齐鲁制药集团总裁李燕,副总裁孙同顺、申丽陪同参观。

查看详情 +

03

/

09

Company News

新闻联播、人民日报、新华社、经济日报、科技日报传递两会齐鲁好声音

举世瞩目的十三届全国人大五次会议3月5日在北京隆重开幕。随山东团出席本次大会的全国人大代表、齐鲁制药集团总裁李燕,向大会提交了多份人大建议,内容涉及民族医药产业高质量发展、儿童及青少年健康成长与教育、个人信息保护等领域。建议内容得到了媒体的广泛关注,并被中央广播电视总台《新闻联播》、人民日报、新华社、经济日报、科技日报等中央媒体报道。

查看详情 +

07

/

27

Company News

新浪财经丨不靠海不临港,济南外贸何以增长近四成

“今年前5个月,公司人用药制剂产品的出口同比增长32.8%,对欧洲市场的出口增长是最主要的拉动因素。”在齐鲁制药集团山东齐鲁医药进出口公司,总经理张晶告诉记者,外贸成为今年公司业绩增长的主要推动力。

查看详情 +

ABOUT US

Originated from QILU, Universal love to the WORLD

Qilu Pharmaceutical is one of the leading vertically integrated pharmaceutical companies in China focusing on the development, manufacturing and marketing of active pharmaceutical ingredients (APIs) & finished formulations. Qilu currently has 13 subsidiaries, 11 manufacturing sites and over 30000 employees worldwide, 70% of whom are with bachelor’s degree or above. It ranks No.8 in Chinese pharmaceutical industry by sales revenue in 2019. Dedicated to offering more affordable medicines to the world and improving people's well-being, Qilu has exported its products to over 80+ countries.

Qilu Pharmaceutical has always maintained an innovative development strategy guided by the market demand and is achieving its organic growth strategy utilizing a strong pool of 3000+ scientists spread across 5 R&D platforms based in the US (Seattle WA, Boston MA, San Francisco CA) and China (Shanghai, Jinan). To date, Qilu has launched 200+ products with 50+ products “First to launch” in China and 3 products “D181 launch” in US. The company has also a robust pipeline, including 200+ generic products, 30+ biosimilar products and 80+ innovative products.

EXPLORE MORE >>
11

11 Domestic Manufacturing Sites

10 TOP

TOP 10 Chinese Pharma. & Industrial Enterprise

30000 +

30,000+ Employees

300 +

300+ Marketed Products

R & D

以临床价值为导向,以患者为中心

The research team, comprised of over 3,000 members, fully utilizes the innovative drug R&D center technology with global independent intellectual property rights, targeting at the tumor and autoimmune diseases, the team has initiated over 60 new first-in-class drug projects. Qilu plans to market 10 to 12 innovative drugs in the next five years.

图片名称

质量管理

Quality Management

图片名称

药物研发

Research and development

图片名称

科技齐鲁

Technology qilu

图片名称

国际齐鲁

International Qilu

产品中心

齐鲁制药集团聚焦创新药、品牌非专利药两大业务板块,专业从事治疗肿瘤、心脑血管、抗感染、精神系统、神经系统、眼科疾病的制剂及其原料药的研制、生产与销售。在抗肿瘤、抗感染、肝病、自身免疫系统性疾病、代谢疾病等未被满足的重大疾病治疗领域,持续开发“全球新”“全球好”药物。

齐鲁制药有限公司
齐鲁制药有限公司
齐鲁制药有限公司

 

Tel: +86-531-83127705831277048312770683127711

Address: 8888 Lvyou Road, High-tech Zone, Jinan, 250104, China

Email:export@qilu-pharma.com


监督举报

亲爱的合作伙伴:

欢迎举报以下行为!

索贿、暗箱操纵招标、内定中标单位、员工或亲属参与公司业务往来牟取私利、偷工减料、以次充好、故意刁难供应商等行为。

举报电话:0531-83126898/55820713/83126871

举报邮箱:qljc@qilu-pharma.com

收信地址:山东省济南市历城区旅游路8888号

齐鲁制药集团审计监察部

采购平台技术专线